The LIMA1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte host cell line. This product provides a heterogeneous pool of cells carrying targeted disruption of the LIMA1 gene, enabling loss-of-function studies without clonal selection artifacts. As a polyclonal knockout model, it is well suited for investigating the collective effects of LIMA1 deficiency in B cell biology and for assays that benefit from population-level functional analysis.
Raji cells are an Epstein-Barr virus (EBV)-positive human B lymphocyte line originally isolated from a Burkitt’s lymphoma patient. These suspension-adapted cells retain properties of mature B cells, including antibody production and antigen presentation capabilities, making them a widely utilized model in lymphoma research and immunological studies. Their robust proliferation and consistent growth characteristics facilitate reproducible genetic perturbation experiments and downstream functional assays.
LIMA1 (EPLIN) encodes an actin-bundling protein that crosslinks filamentous actin. It localizes to adherens junctions and focal adhesions, interacting with ??-catenin (CTNNB1), ??-catenin (CTNNA1), E-cadherin (CDH1), vinculin (VCL), and ??-actin (ACTB). Transcription factors ZEB1 and SNAI1 repress LIMA1 expression downstream of TGF?? (TGFB1), promoting epithelial-mesenchymal transition (EMT). LIMA1 loss destabilizes cadherin-based junctions and enhances migration. Wnt pathway components CTNNB1 and RHOA also intersect with LIMA1-mediated cytoskeletal regulation.
In the context of Raji B lymphocytes, LIMA1 knockout may dysregulate actin-dependent processes central to lymphoma biology, including B cell receptor (BCR) clustering, immune synapse formation, and directional migration. LIMA1 deficiency could alter adhesion dynamics and mechanosensing, potentially influencing the aggressive, disseminating behavior characteristic of Burkitt’s lymphoma. This polyclonal knockout model allows the exploration of how actin-bundling defects affect B cell signal transduction, apoptosis resistance, and interactions with the tumor microenvironment, without the confounding influence of clonal selection.
Researchers can utilize this knockout model in a broad spectrum of experimental workflows. Western blotting and RT-qPCR confirm target gene disruption, while immunofluorescence and phalloidin staining reveal changes in actin cytoskeleton architecture. Flow cytometry enables profiling of surface adhesion markers, and cell adhesion and transmigration assays directly measure functional consequences on B cell motility and homing. Co-immunoprecipitation experiments can dissect LIMA1??s molecular interactions with the E-cadherin/??-catenin complex. Additionally, proliferation and drug sensitivity assays support drug target validation efforts in lymphoma. For further technical details, please contact Ascent Research.
